

Verquvo (vericiguat)

| Member and Medication Information | |
|---|---|
| * indicates required field | |
| *Member ID: | *Member Name: |
| *DOB: | *Weight: |
| *Medication Name/Strength: | <input type="checkbox"/> Do Not Substitute. Authorizations will be processed for the preferred Generic/Brand equivalent unless specified. |
| *Directions for use: | |
| Provider Information | |
| * indicates required field | |
| *Requesting Provider Name: | *NPI: |
| *Address: | |
| *Contact Person: | *Phone #: |
| *Fax #: | Email: |
| Fax form and relevant documentation including: laboratory results, chart notes and/or updated provider letter to Pharmacy PA at 855-828-4992 , to prevent processing delays. | |

Criteria for Approval (ALL of the following criteria must be met):

- Diagnosed with symptomatic chronic heart failure with an ejection fraction 45% or less and either:
 - Hospitalized due to heart failure within last 6 months. **OR**
 - Required IV diuretics as an outpatient within the previous 3 months.
- 18 years of age or older.
- Not pregnant.
- Not taking other soluble guanylate cyclase stimulators (e.g. riociguat).
- Concurrently receiving one or more guideline-directed medications for heart failure with reduced ejection fraction (unless not tolerated or contraindicated). Examples include:
 - Beta-blockers (carvedilol, metoprolol succinate, or bisoprolol).
Medication and dose: _____
 - Angiotensin antagonist (ARNI, ACEI, ARB).
Medication and dose: _____
 - Mineralocorticoid receptor antagonist (e.g. spironolactone) if LVEF < 35% or LVEF ≤ 40% with diabetes mellitus or post myocardial infarction with HF symptoms.
Medication and dose: _____
 - Sodium-glucose cotransporter 2 (SGLT2 inhibitor) e.g. dapagliflozin or empagliflozin.
Medication and dose: _____

Re-authorization Criteria:

Updated letter with medical justification or updated chart notes demonstrating positive clinical response.

Initial Authorization: Up to six (6) months

Re-authorization: Up to one (1) year

PROVIDER CERTIFICATION

I hereby certify this treatment is indicated, necessary and meets the guidelines for use.

Prescriber's Signature

Date